Sargent Investment Group LLC Sells 2,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sargent Investment Group LLC decreased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 122,580 shares of the company’s stock after selling 2,000 shares during the period. Sargent Investment Group LLC’s holdings in Teva Pharmaceutical Industries were worth $1,992,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its holdings in shares of Teva Pharmaceutical Industries by 13.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after acquiring an additional 164,614 shares in the last quarter. QRG Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 53.7% during the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock valued at $2,028,000 after purchasing an additional 50,247 shares in the last quarter. Capital Wealth Planning LLC purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter worth $2,169,000. Public Employees Retirement Association of Colorado lifted its stake in shares of Teva Pharmaceutical Industries by 1,382.8% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock worth $2,671,000 after buying an additional 238,573 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Teva Pharmaceutical Industries by 12.0% during the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after buying an additional 65,529 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The sale was disclosed in a filing with the SEC, which is available at this link. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 1.8 %

TEVA stock opened at $18.07 on Tuesday. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $19.08. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm’s fifty day moving average is $17.59 and its 200 day moving average is $15.99. The firm has a market cap of $20.47 billion, a PE ratio of -44.07, a P/E/G ratio of 1.26 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. On average, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Bank of America raised their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.